COMP <GO>
TMO vs CAT // REVENUE GROWTH (YOY)
Thermo Fisher Scientific Inc (NYSE) VS. Caterpillar Inc. (NYSE) • 15-METRIC TALLY: TMO 5
— CAT 10
▲ REVENUE GROWTH (YOY) LEADER: CAT
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
revenue-growth
3.90%
LAST: $622.75 (-3.81%) • MKT CAP: $286.26B
revenue-growth
18.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMO VS. CAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMO | CAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 82.20% | -41.20 | CAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.30% | 21.15% | -11.85 | CAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 30.4x | 20.9x | +9.54 | CAT | /valuation <GO> |
| Free Cash Flow Yield | 2.40% | 3.74% | -1.34 | CAT | /fcf-yield <GO> |
| Operating Margin | 17.40% | 17.52% | -0.12 | CAT | /operating-margins <GO> |
| Net Profit Margin | 15.10% | 14.51% | +0.59 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 3.90% | 18.36% | -14.46 | CAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 1.05% | -0.81 | CAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.50 | 4.34 | +0.16 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 8.46% | -1.76 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.1 | 23.6 | +35.56 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.02 | -0.08 | CAT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.3x | 26.0x | +10.34 | CAT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $262.22B | $286.26B | -$24.05B | CAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMO REV | CAT REV | TMO GROSS % | CAT GROSS % | TMO FCF | CAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.56B | $67.59B | 44.0% | 99.9% | $6.29B | $8.92B |
| FY 2024 | $42.88B | $64.81B | 44.0% | 100.0% | $7.27B | $10.05B |
| FY 2023 | $42.86B | $67.06B | 44.0% | 99.8% | $6.48B | $11.29B |
| FY 2022 | — | $59.43B | — | 99.3% | — | $6.47B |
| FY 2021 | — | $50.97B | — | 30.3% | — | $6.11B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMO // BETA 0.94
CAT // BETA 1.02